Estrogen therapy linked to doubled odds of porphyria cutanea tarda
A Danish matched case-control study linked estrogen-containing therapy with 2.03-fold adjusted odds of porphyria cutanea tarda; oral therapy showed elevated odds, while non-oral routes did not.